Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje(Massachusetts General Hospital), James N. Kochenderfer(National Institutes of Health), M. Travis Quigley(Bluebird Bio (United States)), David S. Siegel(Hackensack Meridian Health), Sundar Jagannath(Mount Sinai Hospital), Marcela V. Maus(Center for Cancer Research), Julie Wang(Shanghai Jiao Tong University), Greg Russotti(Dana-Farber Cancer Institute), Nikhil C. Munshi(Dana-Farber Cancer Institute), Kristen Hege(University of California, San Francisco), Jesús G. Berdeja(Tennessee Oncology), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Monica Massaro(Healthwise), Kevin M. Friedman(Dana-Farber Cancer Institute), Michaela Liedtke(Cancer Institute (WIA)), Fabio Petrocca(Bristol-Myers Squibb (Sweden)), Yi Lin, Ashley Turka(Bluebird Bio (United States)), Richard A. Morgan(Oak Ridge National Laboratory), Lyh-Ping Lam(Dana-Farber Cancer Institute), Timothy Campbell(Bristol-Myers Squibb (United States)), Zhihong Yang, Deepu Madduri(Johnson & Johnson (United States))
Cited by 1,734
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Long-term outcomes following CAR T cell therapy: what we know so far
|Nature Reviews Clinical Oncology|2023|1.2k